It’s exciting that ARPA-H is focusing on autism, and I think the idea of exploring ways that technology can transform aspects of diagnosis, interventions, and support is timely
in a text
“We can only hope that the review process will lead to an unbiased selection of projects!”
“Novartis now expects to speak with the FDA about a potential accelerated approval of pelabresib before the end of the year, CEO Vas Narasimhan told investors on a call Tuesday.”
“The industry has gotten more consolidated. Prices are higher than ever. Access is worse than ever.”
“The rising costs are unsustainable for individuals, for businesses, and for the country. What kind of intervention is a different question.”